Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005
In a recent subset analysis of the Bezafibrate Infarction Prevention (BIP) trial, investigators looked at the effects of bezafibrate on patients with metabolic syndrome (MS).1 Tenenbaum et al1 reached the conclusions that “bezafibrate reduces the incidence of MI [myocardial infarction] in patients with metabolic syndrome during long-term follow-up,”1(p1154) that bezafibrate was “safe and effective in the secondary prevention of MI in patients with MS,”1(p1159) and that there was a “trend to a 26% reduction of cardiac mortality rate.”1(p1156) They also stated that in patients with augmented features of MS (4-5 risk factors), “the remarkable strengthening of cardiac mortality reduction when taking bezafibrate . . . should be noted.”1(p1154)
McCormack J, Loewen P. The Other Side of the Bezafibrate Infarction Prevention Trial Data. Arch Intern Med. 2005;165(20):2431–2432. doi:10.1001/archinte.165.20.2431
Customize your JAMA Network experience by selecting one or more topics from the list below.